Viewpoint febuxostat, a nonpurine selective inhibitor of xanthine oxidase: Apromising medical therapy for chronic heart failure?

Chinese Medical Journal

Volumn 123, Issue 17, 2010, Pages 2471-2474

  Gao, Ling Gen ^a   Yao, Xiu Ping ^b   Zhang, Lin ^a   Wen, Dan ^a   Luo, Fang ^a   Zhou, Xian Liang ^a   Hui, Ru Tai ^a  

^a FUWAI HOSPITAL   (China)

^b GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Chronic heart failure; Febuxostat; Reactive oxygen species; Signaling pathways; Xanthine oxidase inhibitors

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; REACTIVE OXYGEN METABOLITE; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR; THIAZOLE DERIVATIVE;

ARTICLE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; NONHUMAN; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; ANIMAL; CHRONIC DISEASE; DRUG ANTAGONISM; METABOLISM; REVIEW;

ANIMALS; CHRONIC DISEASE; HEART FAILURE; HUMANS; REACTIVE OXYGEN SPECIES; THIAZOLES; XANTHINE OXIDASE;

EID: 79851480604     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.17.033     Document Type: Article

References (47)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29: 2388-2442.
2. Minaga T, Takeda K, Nakamura T, Kizu A, Ijichi H. Effect of xanthine oxidase inhibitor on myocardial ischemia. RecentAdv Stud Cardiac Struct Metab 1976; 11: 555-558.
3. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90: 297-304.
4. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing induced heart failure. Circulation 2001; 103: 750-755.
5. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing induced heart failure. Circ Res 1999; 5: 437-445.
6. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 20: 2407-2411.
7. Amado LC, Saliaris AP, Raju SV, Lehrke S, St John M, Xie J, et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol 2005; 3: 531-536.
8. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, et al. Allopurinol attenuates leftventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 2004; 15: 2175-2179.
9. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marban E, Weiss RG. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol 2006; 2: H837-H843.
10. Minhas KM, Saraiva RM, Schuleri KH, Lehrke S, Zheng M, Saliaris AP, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 2006; 2: 271-279.
11. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461.
12. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease-molecular mechanisms andpathophysiologic implications. J Physiol 2004; 555: 589-606.
13. Zhang J, Wilke N, Wang Y, Zhang Y, Wang C, Eijgelshoven MH, et al. Functional and bioenergetic consequences of postinfarction left ventricular remodeling in a new porcine model. MRI and 31P-MRS study. Circulation 1996; 94: 1089-1100.
14. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-2196.
15. Echtay KS, Roussel D, St-Pierre J, Jekabsons MB, Cadenas S, Stuart JA, et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002; 415: 96-99.
16. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H2O2 regulates cardiac myocyte phenotype viaconcentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 2003; 35: 615-621.
17. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy tofailure. Hypertension 2002; 40: 477-484.
18. Date MO, Morita T, Yamashita N, Nishida K, Yamaguchi O, Higuchi Y, et al. The antioxidant N-2-mercaptopropionylglycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J Am Coll Cardiol 2002; 39: 907-912.
19. Higuchi Y, Otsu K, Nishida K, Hirotani S, Nakayama H, Yamaguchi O, et al. Involvement of reactive oxygenspecies-mediated NF-kappa B activation in TNF-alphainduced cardiomyocyte hypertrophy. J Mol Cell Cardiol 2002; 34: 233-240.
20. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, Oliver-Krasinski J, et al. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 2001; 89: 453-460.
21. Ghosh MC, Wang X, Li S, Klee C. Regulation of calcineurin by oxidative stress. Methods Enzymol 2003; 366: 289-304.
22. He X, Liu Y, Sharma V, Dirksen RT, Waugh R, Sheu SS, et al. ASK1 associates with troponin T and induces troponin Tphosphorylation and contractile dysfunction incardiomyocytes. Am J Pathol 2003; 163: 243-251.
23. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500-508.
24. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 2004; 10: 1699-1711.
25. Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest 2005; 115: 518-526.
26. 2+-ATPase of cardiac sarcoplasmic reticulum. Mol CellBiochem 2003; 248: 41-47.
27. Srivastava S, Chandrasekar B, Bhatnagar A, Prabhu SD. Lipid peroxidation-derived aldehydes and oxidative stress in thefailing heart: role of aldose reductase. Am J Physiol Heart Circ Physiol 2002; 283: H2612-H2619.
28. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardialfluid of patients with heart failure: a potential role for in vivooxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 97: 1536-1539.
29. Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophicand apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003; 5: 731-740.
30. Ferdinandy P, Panas D, Schulz R. Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rathearts. Am J Physiol 1999; 276: H1861-H1867.
31. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-inducedmyocardial contractile failure. Circ Res 2000; 87: 241-247.
32. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, et al. Imbalance between xanthine oxidase and nitricoxide synthase signaling pathways underlies mechano-energetic uncoupling in the failing heart. Circ Res. 2002; 90: 297-304.
33. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, et al. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol 2000; 32: 2083-2089.
34. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19: 1814-1822.
35. Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiaccontractility in murine postischemic cardiomyopathy. Circ Res 2004; 95: 1005-1011.
36. Hare JM, Stamler JS. NO/redox disequilibrium in the failingheart and cardiovascular system. J Clin Invest 2005; 115:509-517.
37. Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD, et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitationcontractioncoupling. Proc Natl Acad Sci U S A 2004; 101: 15944-15948.
38. Bonaventura J, Gow A. NO and superoxide: opposite ends of the seesaw in cardiac contractility. Proc Natl Acad Sci USA 2004; 101: 16403-16404.
39. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heartfailure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-1997.
40. Doehner W, Anker SD. Uric acid in chronic heart failure. Semin Nephrol 2005; 25: 61-66.
41. 2+_itizing property of xanthine oxidase inhibitors. Circ Res 1998; 83: 423-430.
42. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics offebuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005;12: 22-34.
43. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 2006; 45: 821-841.
44. Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serumurate in healthy volunteers. Nucleosides Nucleotides NucleicAcids 2004; 23: 1111-1116.
45. Hou M, Hu Q, Chen Y, Zhao L, Zhang J, Bache RJ. Acute effects of febuxostat, a nonpurine selective inhibitor ofxanthine oxidase, in pacing induced heart failure. J Cardiovasc Pharmacol 2006; 5: 255-263.
46. Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL, et al. Xanthine oxidase inhibition with febuxostat attenuates systolicoverload-induced left ventricular hypertrophy and dysfunctionin mice. J Card Fail 2008; 14: 746-753.
47. Hayashi K, Kimata H, Obata K, Matsushita A, Fukata A, Hashimoto K, et al. Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters. JCard Fail 2008; 3: 238-244.